Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04847232 · ClinicalTrials.gov registry record · Phase 3
Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,690
- Enrollment target
NCT04847232: Clinical Trial Phase 3 study, sponsored by AstraZeneca.
NCT04847232 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 2,690 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (248% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04847232, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,690 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes in participants on chronic hemodialysis with recurrent hyperkalemia.
Primary Outcome
Incidence of the composite endpoint of SCD, all stroke, or hospitalization/intervention/emergency department (ED) visit due to arrhythmias is analyzed based on Cox regression model with treatment and region as covariates. Patients with no events are censored at final clinical assessment, death, or disposition event.
Interventions
- DRUG Sodium Zirconium Cyclosilicate (SZC)
- DRUG SZC Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,690 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 3 |
Why NCT04847232 stopped before completion
NCT04847232 is an interventional study that assigns participants to a tested intervention. Its 2,690 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (248% higher).
The record links to 0 conditions, and to 2 interventions - of which Sodium Zirconium Cyclosilicate (SZC) is the first listed.
NCT04847232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04847232 about?
NCT04847232 is a clinical study titled "Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)". The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes in participants on chronic hemodialysis with recurrent hyperkalemia.
What is the current status of trial NCT04847232?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,690 participants. The study started on 2021-04-30. Estimated completion is 2024-03-07.
What interventions are being tested in trial NCT04847232?
The interventions under investigation include: Sodium Zirconium Cyclosilicate (SZC) (DRUG), SZC Placebo (DRUG).
Who is sponsoring clinical trial NCT04847232?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04847232's enrollment target sits among peer trials
2,690 84th of 2000 higher than 1,917 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05111925 · 2,690 participants
Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI